CABA Latest Press Releases

-- August 13, 2026 --

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 7:30 AM

-- June 3, 2026 --

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress Globe Newswire 7:00 AM

-- May 14, 2026 --

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 7:05 AM

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting Globe Newswire 7:00 AM

-- May 4, 2026 --

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering Globe Newswire 6:35 AM

-- April 28, 2026 --

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel Business Wire 8:00 AM

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel Globe Newswire 8:00 AM

-- April 27, 2026 --

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting Globe Newswire 5:00 PM

-- April 14, 2026 --

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform Business Wire 4:30 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software